Special Issue "Bacterial Cancer Therapy"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Tumor Immunology and Immunotherapy".

Deadline for manuscript submissions: 1 September 2019.

Special Issue Editor

Guest Editor
Assoc. Prof. Che-Hsin Lee

Department of Biological Sciences, National Sun Yat-Sen University Taiwan, Kaohsiung, Taiwan
Website | E-Mail
Interests: bacteria; cancer immunotherapy; oncolytic bacteria; therapeutic cancer vaccine; bacteria-immunotherapy; gene therapy

Special Issue Information

Dear Colleagues,

This Special Issue, “Bacterial Cancer Therapy”, will mainly focus on bacteria and their induced antitumor activity.

One of the primary limitations of cancer therapy is the lack of selectivity of therapeutic agents to tumor cells. Current efforts are focused on discovering and developing anticancer agents that selectively target only tumor cells but spare normal cells to improve the therapeutic index. The use of preferentially replicating bacteria as an oncolytic agent is one of the innovative approaches for the treatment of cancer. This is based on the observation that some obligate or facultative anaerobic bacteria are capable of multiplying selectively in tumors and inhibiting their growth. Meanwhile, bacteria have been demonstrated to colonize and destroy tumors, and emerged as biological gene vectors to the tumor microenvironment. To improve the efficacy and safety of the bacterial therapy, a further understanding of bacteria in the tumor microenvironment is required.

Assoc. Prof. Che-Hsin Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncolytic bacteria
  • antitumor immunity
  • tumor microenvironment
  • bacteria cancer vaccine
  • immunotherapy
  • combinatorial therapy

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview
Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy
Biomedicines 2019, 7(2), 36; https://doi.org/10.3390/biomedicines7020036
Received: 29 March 2019 / Revised: 25 April 2019 / Accepted: 29 April 2019 / Published: 2 May 2019
PDF Full-text (1076 KB) | HTML Full-text | XML Full-text
Abstract
Presently, cancer is one of the leading causes of death in the world, primarily due to tumor heterogeneity associated with high-grade malignancy. Tumor heterogeneity poses a tremendous challenge, especially with the emergence of resistance not only to chemo- and radiation- therapies, but also [...] Read more.
Presently, cancer is one of the leading causes of death in the world, primarily due to tumor heterogeneity associated with high-grade malignancy. Tumor heterogeneity poses a tremendous challenge, especially with the emergence of resistance not only to chemo- and radiation- therapies, but also to immunotherapy using monoclonal antibodies. The use of Salmonella, as a highly selective and penetrative antitumor agent, has shown convincing results, thus meriting further investigation. In this review, the mechanisms used by Salmonella in combating cancer are carefully explained. In essence, Salmonella overcomes the suppressive nature of the tumor microenvironment and coaxes the activation of tumor-specific immune cells to induce cell death by apoptosis and autophagy. Furthermore, Salmonella treatment suppresses tumor aggressive behavior via inhibition of angiogenesis and delay of metastatic activity. Thus, harnessing the natural potential of Salmonella in eliminating tumors will provide an avenue for the development of a promising micro-based therapeutic agent that could be further enhanced to address a wide range of tumor types. Full article
(This article belongs to the Special Issue Bacterial Cancer Therapy)
Figures

Graphical abstract

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top